Cargando…

995. A quality improvement initiative to increase penicillin allergy clarification and decrease aztreonam usage

BACKGROUND: Penicillin (PCN) allergy is a serious adverse reaction that prevents the use of first-line therapy. 10% of the population reports a PCN allergy; however, less than 1% is truly allergic. Elimination of false allergies significantly impacts patient’s lives and decreases antimicrobial resis...

Descripción completa

Detalles Bibliográficos
Autor principal: rahbani, Peggy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6811020/
http://dx.doi.org/10.1093/ofid/ofz360.859
_version_ 1783462377431236608
author rahbani, Peggy
author_facet rahbani, Peggy
author_sort rahbani, Peggy
collection PubMed
description BACKGROUND: Penicillin (PCN) allergy is a serious adverse reaction that prevents the use of first-line therapy. 10% of the population reports a PCN allergy; however, less than 1% is truly allergic. Elimination of false allergies significantly impacts patient’s lives and decreases antimicrobial resistance and cost. Inova Mount Vernon Hospital (IMVH) has reported lack of pharmacist’s interventions in allergy clarification and counseling thus leading to an increase in aztreonam usage. The primary objective of the study was to increase pharmacist’s interventions in patient allergy clarification and counseling. The secondary objective was to decrease aztreonam duration of therapy (DOT) by 10%. METHODS: This project was conducted and monitored M-F on the pharmacy true north board March-December 2018. The initial step was to create a standard work and educate pharmacists on individualized PCN allergy patients interviewing and counseling. Pharmacist’s interventions tracking were made using the electronic reporting system. To quantify aztreonam usage, duration of therapy (DOT/1000) was collected during the study period and compared with data from 2017. RESULTS: During the study implementation, a total of 551 interventions pertaining to PCN allergy were documented by pharmacists between March-November 2018, compared with only 72 interventions made in March-November 2017 (7x increase, P < 0.005). Pharmacists while intervening clarified the allergy added the severity of the reaction, documented whether patients recently tolerated any PCN-based antibiotics, and de-labeled patients when appropriate. Allergy assessments lead to a decrease in aztreonam DOT/1000 by 12% in 2018 compared with 2017 and the overall antimicrobial stewardship goal was achieved. CONCLUSION: Pharmacists interventions in allergy clarification helped with antibiotic de-escalation, improved safety, and de-labeled patients when appropriate. This initiative also increased physician and nursing awareness of the importance of clarifying PCN allergies. After successfully hardwiring this practice the pharmacy is partnering with nursing to implement PCN skin testing service at IMVH. DISCLOSURES: All authors: No reported disclosures.
format Online
Article
Text
id pubmed-6811020
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-68110202019-10-28 995. A quality improvement initiative to increase penicillin allergy clarification and decrease aztreonam usage rahbani, Peggy Open Forum Infect Dis Abstracts BACKGROUND: Penicillin (PCN) allergy is a serious adverse reaction that prevents the use of first-line therapy. 10% of the population reports a PCN allergy; however, less than 1% is truly allergic. Elimination of false allergies significantly impacts patient’s lives and decreases antimicrobial resistance and cost. Inova Mount Vernon Hospital (IMVH) has reported lack of pharmacist’s interventions in allergy clarification and counseling thus leading to an increase in aztreonam usage. The primary objective of the study was to increase pharmacist’s interventions in patient allergy clarification and counseling. The secondary objective was to decrease aztreonam duration of therapy (DOT) by 10%. METHODS: This project was conducted and monitored M-F on the pharmacy true north board March-December 2018. The initial step was to create a standard work and educate pharmacists on individualized PCN allergy patients interviewing and counseling. Pharmacist’s interventions tracking were made using the electronic reporting system. To quantify aztreonam usage, duration of therapy (DOT/1000) was collected during the study period and compared with data from 2017. RESULTS: During the study implementation, a total of 551 interventions pertaining to PCN allergy were documented by pharmacists between March-November 2018, compared with only 72 interventions made in March-November 2017 (7x increase, P < 0.005). Pharmacists while intervening clarified the allergy added the severity of the reaction, documented whether patients recently tolerated any PCN-based antibiotics, and de-labeled patients when appropriate. Allergy assessments lead to a decrease in aztreonam DOT/1000 by 12% in 2018 compared with 2017 and the overall antimicrobial stewardship goal was achieved. CONCLUSION: Pharmacists interventions in allergy clarification helped with antibiotic de-escalation, improved safety, and de-labeled patients when appropriate. This initiative also increased physician and nursing awareness of the importance of clarifying PCN allergies. After successfully hardwiring this practice the pharmacy is partnering with nursing to implement PCN skin testing service at IMVH. DISCLOSURES: All authors: No reported disclosures. Oxford University Press 2019-10-23 /pmc/articles/PMC6811020/ http://dx.doi.org/10.1093/ofid/ofz360.859 Text en © The Author(s) 2019. Published by Oxford University Press on behalf of Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Abstracts
rahbani, Peggy
995. A quality improvement initiative to increase penicillin allergy clarification and decrease aztreonam usage
title 995. A quality improvement initiative to increase penicillin allergy clarification and decrease aztreonam usage
title_full 995. A quality improvement initiative to increase penicillin allergy clarification and decrease aztreonam usage
title_fullStr 995. A quality improvement initiative to increase penicillin allergy clarification and decrease aztreonam usage
title_full_unstemmed 995. A quality improvement initiative to increase penicillin allergy clarification and decrease aztreonam usage
title_short 995. A quality improvement initiative to increase penicillin allergy clarification and decrease aztreonam usage
title_sort 995. a quality improvement initiative to increase penicillin allergy clarification and decrease aztreonam usage
topic Abstracts
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6811020/
http://dx.doi.org/10.1093/ofid/ofz360.859
work_keys_str_mv AT rahbanipeggy 995aqualityimprovementinitiativetoincreasepenicillinallergyclarificationanddecreaseaztreonamusage